Trial Profile

A randomized, double-blind, placebo-controlled, single- and multiple-ascending dose Phase 1 trial of ABS-0871 in healthy volunteers that will evaluate safety, tolerability, pharmacokinetics, and measures of pharmacodynamic activity.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 15 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABS 0871 (Primary)
Indications Bone disorders; Charcot marie tooth disease type 2C; Overactive bladder
Focus Adverse reactions

03 Mar 2025 According to an Actio Biosciences media release, first participant has been dosed in this trial.
03 Mar 2025 Status changed from planning to recruiting, according to a Actio Biosciences media release.
25 Sep 2024 According to Actio Biosciences media release, the Charcot-Marie-Tooth Disease, Type 2C (CMT2C) program is expected to enter a Phase 1 clinical trial by year-end 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com